Report Highlights

The U.S. Role in the Global Respiratory Drug Supply Chain

The United States consumes more asthma and COPD drugs than any other market, yet domestic manufacturing covers only part of that demand. Boehringer Ingelheim's Ridgefield, Connecticut facility and AstraZeneca's Newark, Delaware site anchor inhaler assembly, while active pharmaceutical ingredients arrive largely from India and China. Finished respiratory dosage forms and biologic injectables arrive from Ireland, Germany and Sweden. Import dependency on Chinese and Indian intermediates leaves the chain's upstream exposed to single-country shocks.

Value capture sits in the United States at formulation, device engineering and brand marketing rather than in commodity production. Pharmaceutical exports of respiratory products flow chiefly to Canada, Mexico and the Netherlands, where U.S.-developed brands are repackaged for European and Latin American distribution. Air cargo through Memphis and Ontario, California moves cold-chain biologics, making logistics reliability a strategic vulnerability for national supply. Dispensing volumes concentrate in retail chains such as CVS Health and Walgreens.

Growth Drivers for U.S. Respiratory Drug Trade and Production

Rising COPD prevalence among adults over 65 and sustained asthma incidence in urban counties are lifting dispensing volumes through Medicare Part D and commercial formularies. This demand is pulling inhaler device production toward domestic lines, as manufacturers announced U.S. capacity commitments throughout 2025 to shield supply from Section 232 pharmaceutical tariff exposure. Investment that previously targeted European sites is shifting toward American plants to match this shift.

Biologic penetration is the second driver, as injectable add-on therapies for eosinophilic asthma require refrigerated distribution networks that favour specialty logistics providers. Import substitution advances through generic dry powder inhalers, where Teva, Viatris and Cipla are scaling U.S. approvals and reducing reliance on branded imports. The third driver is cold-chain investment at Memphis and Ontario hubs, which lowers temperature-excursion losses and widens biologic distribution to rural pharmacies.

Supply Chain Risks and Trade Barriers for U.S. Respiratory Drugs

Section 232 investigations into pharmaceutical imports threaten tariff exposure on finished inhalers and biologics sourced from Ireland, Germany and Sweden. Any duty increase raises landed costs for products whose Medicare reimbursement is fixed, so manufacturers absorb margin compression rather than passing costs to patients. Euro-denominated contracts with European fill-finish partners add currency risk, as dollar budgets swing against the euro each quarter.

Upstream concentration in active pharmaceutical ingredients from China and India leaves U.S. respiratory supply exposed to port disruption, export controls and quality failures at single plants. FDA warning letters to Indian and Chinese API facilities have repeatedly interrupted albuterol and generic inhaler output. Logistics gaps in cold-chain air freight and rural last-mile delivery compound the vulnerability, delaying biologic doses for patients in underserved counties.

Trade and Investment Opportunities in the United States

Nearshoring inhaler device assembly to Mexico offers the most direct cost lever, because USMCA-qualifying components enter the United States without duty. Generic dry powder inhaler producers should evaluate Monterrey and Tijuana contract manufacturers for final assembly, targeting duty-free re-entry under existing rules of origin. Foreign Trade Zone designations at Memphis and Ontario allow importers to defer duties on biologic inventory until distribution.

Domestic fill-finish capacity for biologics represents an underserved investment opportunity, given that imported injectables currently route through Ireland and Germany before reaching U.S. wholesalers. Logistics hub development at Memphis and Ontario can attract third-party cold-chain operators serving Canada and Mexico, extending U.S. distribution into North American export lanes. Investors should target contract manufacturers able to handle lyophilized biologics at scale.

Market at a Glance

Leading Market Participants

• AstraZeneca
• GlaxoSmithKline
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Teva Pharmaceutical Industries
• Sanofi
• Regeneron Pharmaceuticals
• Viatris
• Cipla
• Novartis

Regulatory and Trade Policy Environment

The United States Mexico Canada Agreement allows qualifying respiratory devices and components to enter duty-free, provided they satisfy rules of origin. The 2025 U.S.-EU framework agreement caps most pharmaceutical tariffs for EU-origin goods, shaping cost planning for Irish and German inhaler imports. Section 232 investigations remain the principal tariff risk for branded respiratory products.

FDA approval pathways govern market entry, with generic complex inhalers requiring product-specific bioequivalence studies under agency guidance. The Drug Supply Chain Security Act requires electronic product tracing and serialization across distribution, adding compliance cost for wholesalers handling respiratory products. Medicare Part D price negotiation under the Inflation Reduction Act shapes net pricing for qualifying drugs, influencing manufacturer decisions on domestic capacity investment.

U.S. Respiratory Drug Supply Chain Outlook to 2032

U.S. respiratory drug supply chains will shift toward domestic device assembly and biologic fill-finish through 2032, as tariff policy rewards onshored production. Trade flows will move from bulk European imports toward Mexican device assembly and American finished-goods manufacturing, shortening lead times for inhaler replenishment. Memphis and Ontario logistics infrastructure will expand cold-chain throughput to match biologic volume growth.

Technology changes will alter comparative advantage, particularly digital inhaler sensors and connected devices that move value toward software and data-enabled device makers. Companies holding biologic manufacturing know-how in the United States will capture higher margins as generic dry powder inhaler competition intensifies. The 2032 supply chain will reward firms that combine domestic capacity with diversified API sourcing beyond India and China.